Skip to main content
HERAMED LIMITED logo

HERAMED LIMITED — Investor Relations & Filings

Ticker · HMD ISIN · AU0000028367 LEI · 875500WOB41XBFTTJ477 ASX Manufacturing
Open in API
Filings indexed 524 across all filing types
Latest filing 2021-08-31 Capital/Financing Update
Country AU Australia
Listing ASX HMD

About HERAMED LIMITED

https://hera-med.com/

HeraMED Limited is a medical technology company specializing in the development and commercialization of digital health solutions for maternity care. The company focuses on providing remote monitoring tools that bridge the gap between expectant mothers and healthcare providers. Its flagship product, HeraBEAT, is a medical-grade, smartphone-based fetal heart rate monitor designed for home use, allowing for accurate and reliable monitoring of fetal well-being. This hardware is integrated into the HeraCARE platform, a comprehensive digital maternity care solution that enables remote data management, personalized care plans, and seamless communication between patients and clinicians. By leveraging cloud-based technology and advanced sensors, the company aims to enhance prenatal care, improve clinical outcomes, and offer peace of mind through continuous, data-driven insights throughout the pregnancy journey.

Recent filings

Filing Released Lang Actions
HeraCARE Shortlisted for Government tender in Spain 3 pages 210.5KB
Capital/Financing Update Classification · 95% confidence The document is an ASX announcement dated 01 September 2021 regarding HeraMED Limited being shortlisted for a government tender in Spain and signing a Memorandum of Understanding (MOU) with Hospital Hispania. It discusses the potential commercial collaboration, product details, and expected revenues but does not contain any financial statements, quarterly or annual results, or detailed financial analysis. It is a corporate announcement about a business development and partnership opportunity rather than a financial report or regulatory filing. The document length is 8181 characters, which is substantial but the content is clearly an announcement of a business event. Therefore, the most appropriate classification is Capital/Financing Update (CAP) as it relates to a commercial collaboration and potential revenue generation through a government tender and partnership agreement.
2021-08-31 English
Appendix 4D and Half Year Report 25 pages 980.0KB
Interim / Quarterly Report Classification · 100% confidence The document is titled 'ASX APPENDIX 4D HALF-YEAR FINANCIAL REPORT TO 30 JUNE 2021' and contains detailed financial data for the half-year period ending 30 June 2021, including profit/loss figures, net tangible assets per share, and a directors' report. It also includes an auditor's review report and consolidated financial statements. The presence of comprehensive financial statements and management commentary for a half-year period clearly identifies this as an Interim / Quarterly Report. The document length is substantial (15,000 characters), and it contains actual financial data and analysis, not just an announcement or certification. Therefore, the correct classification is 'IR' (Interim / Quarterly Report). H1 2021
2021-08-26 English
Cleansing Prospectus 29 pages 348.8KB
Capital/Financing Update Classification · 100% confidence The document is titled 'PROSPECTUS' and details an offer of shares in the company HeraMED Limited. It includes sections such as corporate directory, timetable, details of the offer, purpose and effect of the offer, rights and liabilities attaching to shares, risk factors, and other information typical of a prospectus. The document is prepared under section 708A(11) of the Corporations Act to remove trading restrictions on shares issued prior to the closing date. It is clearly an offering document for new shares, describing the terms, conditions, and legal disclaimers related to the share offer. This matches the definition of a capital raising or financing update document. Therefore, the appropriate classification is Capital/Financing Update (CAP).
2021-08-15 English
HeraCARE paid pilot commences at Joondalup Health Campus 2 pages 165.0KB
Regulatory Filings Classification · 95% confidence The document is an ASX announcement dated 13 August 2021, describing the commencement of a paid pilot program for HeraMED's HeraCARE technology solution at Joondalup Health Campus. It details the pilot's scope, the agreement with the hospital, and background information about the company and the hospital. There are no financial statements, regulatory certifications, or detailed financial data. The document is a corporate announcement about a business development or operational update rather than a financial report or regulatory filing. It does not fit into categories like Annual Report, Interim Report, Earnings Release, or Capital Update. It is not a report publication announcement since it contains substantive information about the pilot commencement. The best fitting category is Regulatory Filings (RNS), which is the fallback for general regulatory announcements and corporate updates that do not fit other categories.
2021-08-12 English
Sheba Expands Pilot to include High-Risk Pregnancies 3 pages 336.9KB
Regulatory Filings Classification · 95% confidence The document is a press release announcing the expansion of a pilot tele-health study involving HeraBEAT and HeraCARE devices at Sheba Medical Centre. It describes the pilot stages, the technology involved, and the collaboration between HeraMED and Sheba Medical Centre. There are no financial statements, regulatory filings, voting results, or management changes. The content focuses on a clinical pilot program and partnership announcement rather than financial or regulatory reporting. It is not an annual or interim report, earnings release, or any other formal financial filing. Therefore, the document best fits the category of a general regulatory announcement or miscellaneous company update, which falls under Regulatory Filings (RNS). The document length is 7106 characters, which is sufficient for a detailed announcement but does not contain financial data or formal report content.
2021-08-01 English
Quarterly Activities & Cashflow Report 7 pages 283.3KB
Interim / Quarterly Report Classification · 95% confidence The document is an ASX announcement dated 29 July 2021 providing a quarterly update on HeraMED's commercial progress and financial overview for Q2 FY21 ending 30 June 2021. It includes detailed financial data such as cash flows from operating, investing, and financing activities, staff costs, marketing expenses, and cash balances. The document also contains the Appendix 4C quarterly cash flow report, which is a regulatory requirement for Australian listed entities to report quarterly cash flows. The presence of substantive financial data and analysis for a quarter shorter than a full fiscal year, along with the quarterly cash flow report, indicates this is an Interim / Quarterly Report. It is not merely an announcement of a report but contains actual financial statements and analysis. Therefore, the appropriate classification is Interim / Quarterly Report (IR). Q2 2021
2021-07-28 English

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.